By Billy Candra 
This significant medical advancement, spearheaded by Cambridge University Hospitals (CUH) NHS Foundation Trust and the University of Cambridge, reveals that a carefully timed combination of chemotherapy and a targeted cancer drug, olaparib, administered before surgery, led to 100% of patients surviving the critical three-year period post-surgery in a recent trial. The findings, published today in the esteemed journal Nature Communications, represent a potential paradigm shift in the treatment landscape for individuals diagnosed with early-stage breast cancer carrying inherited BRCA1 and BRCA2 gene mutations, potentially becoming the most effective therapeutic strategy to date for this challenging patient group.
A New Horizon for BRCA-Mutated Breast Cancers
Breast cancers linked to faulty copies of the BRCA1 and BRCA2 genes are notoriously aggressive and complex to treat. These genetic mutations garnered widespread public attention in 2013 when actress Angelina Jolie, a carrier of the BRCA1 mutation, openly discussed her preventative double mastectomy, raising global awareness about inherited cancer risks. Traditionally, the standard treatment protocol for these cancers involves a regimen of chemotherapy and often immunotherapy aimed at shrinking the tumour, followed by surgical removal. The initial three years following surgery are considered a high-risk window, during which patients face the greatest likelihood of relapse or mortality.
The "Partner trial" embarked on an innovative trajectory, introducing two key deviations from conventional practice. The first was the strategic addition of olaparib, a targeted cancer drug already available on the NHS, alongside chemotherapy before surgery. The second crucial innovation was the meticulous timing of these treatments. Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, is taken orally as tablets and works by preventing cancer cells with faulty DNA repair pathways (like those with BRCA mutations) from repairing themselves, leading to their death.
The trial, led by Addenbrooke’s Hospital, a part of CUH NHS Foundation Trust, and the University of Cambridge, successfully recruited patients from 23 NHS sites across the United Kingdom, showcasing a robust collaborative effort within the national health service and academic research institutions.
The "48-Hour Gap": A Scientific Breakthrough
One of the most compelling insights from the Partner trial revolves around the strategic sequencing of drug administration. Results unequivocally demonstrated that implementing a 48-hour "gap" between the administration of chemotherapy and olaparib yielded superior outcomes. Researchers hypothesize that this specific interval allows a patient’s bone marrow to recover from the cytotoxic effects of chemotherapy, thereby mitigating severe side effects, while simultaneously leaving the tumour cells uniquely susceptible to the subsequent targeted action of olaparib. This finely tuned approach appears to optimize the therapeutic window, enhancing efficacy without unduly increasing toxicity.
Out of the 39 patients who received the innovative regimen of chemotherapy followed by olaparib with the prescribed gap, an astounding 100% survived three years after surgery. Furthermore, only one patient in this cohort experienced a relapse within the three-year follow-up period. This stands in stark contrast to the control arm of the study, where patients received chemotherapy only. In the control group, comprising 45 patients, the three-year survival rate was 88%. A more concerning statistic from the control arm revealed that nine patients relapsed, and tragically, six of these patients succumbed to the disease. The dramatic difference in outcomes underscores the profound impact of the new treatment approach.
A Patient’s Journey: Hope and Renewal
For individuals like Jackie Van Bochoven, 59, from South Cambridgeshire, the trial offered a lifeline. Diagnosed in February 2019 with a small but aggressive tumour, Jackie’s initial reaction mirrored that of many facing a cancer diagnosis. "When I had the diagnosis, I was completely shocked and numb," she recounted, her thoughts immediately turning to her children, and the painful family history of breast cancer that affected her mother and sister. "I was pretty worried."
Today, six years post-diagnosis and treatment, Jackie stands as a testament to the trial’s success. "Six years on, I’m well and cancer free. I’m back at work, enjoying life and spending time with my family," she shared, her voice imbued with gratitude. "When you’ve had cancer, I think you look at life differently and every day is a bonus." Her story is a powerful reminder of the human impact behind the statistics, embodying the hope that such medical breakthroughs offer.
Understanding BRCA Genes and Their Impact
To fully appreciate the significance of this research, it is crucial to understand the role of BRCA1 and BRCA2 genes. These genes are tumour suppressors, meaning they produce proteins that help repair damaged DNA and prevent cells from growing and dividing uncontrollably. When these genes have inherited mutations, their ability to repair DNA is compromised. This cellular dysfunction can lead to the accumulation of further genetic errors, dramatically increasing an individual’s lifetime risk of developing certain cancers, most notably breast and ovarian cancers, but also prostate and pancreatic cancers.
Approximately 5-10% of all breast cancers are thought to be hereditary, with BRCA1 and BRCA2 mutations accounting for a significant proportion of these. For women with a BRCA1 mutation, the lifetime risk of developing breast cancer can be as high as 45-85%, and for ovarian cancer, 11-40%. For BRCA2 mutations, the lifetime risk for breast cancer is similarly elevated at 45-85%, and for ovarian cancer, 10-20%. These statistics underscore the urgent need for highly effective treatments tailored to this genetically predisposed patient population. The Partner trial directly addresses this unmet clinical need by targeting the specific vulnerabilities created by these faulty genes.
Olaparib: A Targeted Therapy Explained
Olaparib, marketed as Lynparza, is a pioneering drug belonging to a class known as PARP inhibitors. PARP enzymes are involved in repairing single-strand breaks in DNA. In cells with normal BRCA function, if a single-strand break occurs and PARP is inhibited, the cell can still rely on the BRCA-mediated homologous recombination repair pathway to fix the damage. However, in cancer cells with mutated BRCA1 or BRCA2 genes, this backup repair mechanism is already faulty. By inhibiting PARP, olaparib effectively creates a "synthetic lethality" – a situation where the combination of two non-lethal defects (PARP inhibition and BRCA mutation) becomes lethal to the cancer cell, while sparing healthy cells.
Olaparib was first approved in 2014 for advanced ovarian cancer patients with BRCA mutations and has since seen its indications expand to include breast, prostate, and pancreatic cancers, demonstrating its broad potential in BRCA-related malignancies. The Partner trial’s innovative use of olaparib pre-surgery and in a specific timed sequence opens up new avenues for optimizing its therapeutic impact.
Broader Implications and Future Trajectories
The implications of the Partner trial extend beyond breast cancer. The findings hold potential applicability for other cancers driven by faulty copies of BRCA genes, including certain ovarian, prostate, and pancreatic cancers. This suggests a broader therapeutic strategy that could benefit a wider array of patients with inherited cancer predispositions.
Economically, the new approach also presents potential cost-saving benefits for the NHS. Current standard practice often involves administering olaparib post-surgery for a duration of 12 months. In contrast, patients on the Partner trial received the tablets pre-surgery for a significantly shorter period of 12 weeks. If validated in larger studies, this shorter, pre-operative regimen could lead to substantial cost efficiencies for the healthcare system while potentially improving patient outcomes.
Professor Jean Abraham, a consultant at Addenbrooke’s and the trial lead, expressed immense enthusiasm for the results. "It is rare to have a 100% survival rate in a study like this and for these aggressive types of cancer," Professor Abraham stated. "We’re incredibly excited about the potential of this new approach, as it’s crucial that we find a way to treat and hopefully cure patients who are diagnosed with BRCA1 and BRCA2 related cancers." Professor Abraham, who also holds the title of Professor of Precision Breast Cancer Medicine at the University of Cambridge, revealed that the inspiration for the 48-hour gap approach stemmed from a "chance conversation" with Mark O’Connor, chief scientist in Early Oncology R&D at nearby AstraZeneca, highlighting the serendipitous nature of scientific discovery fostered by collaborative environments.
Mark O’Connor echoed this sentiment, emphasizing the trial’s significance. "The Partner trial highlights the importance of detecting and treating cancer early, and the value of innovative science in informing clinical trial design, in this case using bone marrow stem cells to identify the combination gap schedule," O’Connor remarked. While acknowledging the need for validation in a larger study, he stressed that the findings are "incredibly exciting, and have the potential to transform outcomes for patient populations who have unmet clinical need."
A Vision for Integrated Cancer Care: Cambridge Cancer Research Hospital
This successful collaboration between the NHS, academia, and industry perfectly embodies the vision behind the forthcoming Cambridge Cancer Research Hospital. This specialist cancer research hospital, slated for construction on Europe’s leading life sciences campus, the Cambridge Biomedical Campus, aims to revolutionize cancer care. It will seamlessly integrate clinical expertise from Addenbrooke’s Hospital with world-class scientists from the University of Cambridge, the Cancer Research UK Cambridge Centre, and industry partners. This singular location will serve as a hub for innovation, dedicated to creating new diagnostics and treatments, detecting the earliest signs of cancer, and delivering truly personalized, precision medicine. The Partner trial serves as a compelling precursor to the type of groundbreaking work expected from this integrated facility.
Michelle Mitchell, Chief Executive of Cancer Research UK, commended the research, stating, "One of the best ways that we can beat cancer sooner is by making more effective use of treatments that are already available to us." She recognized the nascent stage of the research but lauded it as "an exciting discovery that adding olaparib at a carefully-timed stage of treatment can potentially give patients with this specific type of breast cancer more time with their loved ones." Mitchell further underscored the broader impact, noting that "Research like this can help find safer and kinder ways to treat certain types of cancer. Further studies in more patients are needed to confirm whether this new technique is safe and effective enough to be used by the NHS."
The Road Ahead: Larger Studies and Broader Adoption
Professor Abraham and her dedicated team are now meticulously planning the next crucial phase of this research. This subsequent study will aim to replicate the remarkable results in a significantly larger patient cohort. This expansion is vital for robust statistical validation and to definitively confirm that the Partner approach not only offers a more effective treatment but also provides a less toxic and more cost-effective alternative compared to the current standard of care. Such comprehensive validation is a prerequisite for widespread adoption within national healthcare systems.
The Partner trial itself was sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, reflecting a strong institutional commitment to advancing medical science. Crucial funding was provided by Cancer Research UK and AstraZeneca, demonstrating the indispensable role of both charitable organizations and pharmaceutical industry partners in driving innovation. Additional support was garnered from the NIHR Cambridge Biomedical Research Centre, the Cancer Research UK Cambridge Centre, and Addenbrooke’s Charitable Trust (ACT), highlighting a multifaceted network of support essential for pioneering clinical research. This collective effort underscores the collaborative spirit that is increasingly vital in tackling complex diseases like cancer, offering renewed hope for patients facing aggressive, inherited breast cancers.
